Using existing drugs to target protein interactions involved in Alzheimer's disease
Official title: Repurposing FDA-approved drugs to disrupt tau- and amyloid-associated protein-protein interactions in Alzheimer's disease aggregates
Funded at Central Arkansas Veterans Hlthcare Sys · NIH-10925593 · Data updated 2026-11-12
This study is looking at how certain approved medications might help break up harmful protein clumps in the brain that are linked to Alzheimer's disease, with the hope of finding new treatments that could slow down the progression of the condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Central Arkansas Veterans Hlthcare Sys NIH-funded |
| Lab location | 1 site (North Little Rock, United States) |
| Project start | October 1, 2024 |
| Project end | September 30, 2028 |
| Funding year | 2025 |
| NIH project number | 1I01BX006445-01A1 |
| Project ID | NIH-10925593 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those at risk of developing it.
✕Less likely to help
Patients with other forms of dementia unrelated to Alzheimer's disease may not benefit from this research.
What this research studies
This research investigates how FDA-approved drugs can disrupt harmful protein interactions that contribute to Alzheimer's disease. By analyzing protein aggregates in brain tissue, the team identifies specific interactions that are crucial for the disease's progression. They utilize advanced techniques, including machine learning and in-silico screening, to find effective drug candidates that can be tested in laboratory models. The ultimate goal is to find treatments that can reduce protein aggregation and potentially slow down the disease's progression.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively reduce the progression of Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in repurposing existing drugs for neurodegenerative diseases, indicating potential success for this approach.
Where this research is happening
-
Central Arkansas Veterans Hlthcare Sys
North Little Rock, United States Active
Researchers
- Principal investigator: Shmookler Reis, Robert Joseph — Central Arkansas Veterans Hlthcare Sys
- Study coordinator: Shmookler Reis, Robert Joseph
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.